Skip to main content
BIOVENTIX PLC logo

BIOVENTIX PLC — Investor Relations & Filings

Ticker · BVXP ISIN · GB00B4QVDF07 LEI · 213800225MHX7LZQY108 IL Manufacturing
Open in API
Filings indexed 211 across all filing types
Latest filing 2025-10-30 Director's Dealing
Country GB United Kingdom
Listing IL BVXP

About BIOVENTIX PLC

https://www.bioventix.com/

Bioventix PLC is a biotechnology company that specializes in the development, creation, and commercial supply of high-affinity sheep monoclonal antibodies (SMAs). These antibodies are utilized by global diagnostic companies as critical components in clinical diagnostic platforms, particularly for blood testing immunoassays. The company's portfolio supports a variety of applications, including diagnostics for cardiovascular conditions (troponin), oncology, and neurodegenerative diseases such as Alzheimer's. In addition to its core antibody products, Bioventix also provides ELISA kits for monitoring exposure to industrial pollutants and offers contract services for the development of new SMAs for healthcare organizations.

Recent filings

Filing Released Lang Actions
Director Dealing
Director's Dealing Classification · 100% confidence The document is an official notification of a share purchase by a company director (Ian Nicholson, Non-Executive Chairman of Bioventix PLC). It explicitly uses the header 'Director Dealing' and includes the required 'Notification and public disclosure of transactions by persons discharging managerial responsibilities' (PDMR) table as mandated by the EU Market Abuse Regulation. This fits the definition of a Director's Dealing (DIRS) filing.
2025-10-30 English
Director Dealing
Director's Dealing Classification · 100% confidence The document is an official notification of a share purchase by a person discharging managerial responsibilities (PDMR), specifically the Chief Financial Officer, Bruce Hiscock. It includes the required disclosure table for transactions by persons discharging managerial responsibilities under the EU Market Abuse Regulation. This fits the definition of a Director's Dealing (DIRS) filing.
2025-10-27 English
Results for the year ended 30 June 2025
Earnings Release Classification · 100% confidence The document is an 'Earnings Release' (ER) for BioVentix PLC. It contains the company's financial highlights for the year ended 30 June 2025, including revenue, profit before tax, cash position, and dividend announcements. It follows the standard structure of an earnings announcement, providing a summary of performance, market factors (such as the Chinese market impact), and operational updates. It is not a full Annual Report (10-K) as it is an announcement of results rather than the full statutory filing, and it is not an RPA because it contains the actual financial data and commentary rather than just a notification of publication. FY 2025
2025-10-27 English
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is a 'TR-1: Standard form for notification of major holdings'. This is a regulatory requirement for shareholders to disclose when their voting rights in a company cross a specific threshold (in this case, 5.04%). This falls directly under the definition of a Major Shareholding Notification.
2025-08-13 English
Director Dealing
Director's Dealing Classification · 99% confidence The document explicitly states it is an announcement regarding a 'Director Dealing' where the Chief Financial Officer purchased company shares. The structure includes an RNS Number, notification details, and a formal table detailing the transaction in accordance with EU Market Abuse Regulation. This directly corresponds to the definition of 'Director's Dealing' (Code: DIRS). The presence of 'RNS Number' and the closing statement about RNS being the news service of the London Stock Exchange confirms it is a regulatory disclosure, but the specific content points overwhelmingly to DIRS.
2025-04-28 English
Exercise of Options and Issue of Equity
Director's Dealing Classification · 95% confidence The document is an RNS announcement from Bioventix PLC detailing the exercise of share options by the CEO (a PDMR) and the subsequent change in total voting rights. This falls under the category of Director's Dealing (DIRS) as it reports personal share transactions by a company executive, and also includes information on capital changes (SHA). Given the primary focus on the director's transaction and the mandatory PDMR disclosure format, DIRS is the most accurate classification.
2025-04-11 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.